Granulocyte macrophage--colony stimulating factor (GM-CSF) as adjunct in induction therapy of acute myeloid leukemia.
Indian J Cancer
;
1999 Mar; 36(1): 32-7
Artigo
em Inglês
| IMSEAR
| ID: sea-50305
ABSTRACT
Use of growth factors (G-CSF/GM-CSF) as adjunct in induction therapy of AML is controversial. Possible stimulation of leukemia cell clones has been the major cause of concern. We treated 50 cases of AML with GM-CSF as an adjunct during induction therapy. 35 patients (70%) achieved complete remission out of which 13 patients relapsed at a median relapse period of 15 months. Average duration of neutropenia was 10.5 days. (15 days in the control) Febrile episodes were fewer and antibiotic support was required for an average period of only 7.6 days (16.9 days in the control). The benefits including the economic analysis of the role of GM-CSF in this setting is discussed.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Indução de Remissão
/
Feminino
/
Humanos
/
Masculino
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Daunorrubicina
/
Leucemia Mieloide
/
Adjuvantes Imunológicos
/
Doença Aguda
/
Seguimentos
Tipo de estudo:
Estudo observacional
/
Estudo prognóstico
Idioma:
Inglês
Revista:
Indian J Cancer
Ano de publicação:
1999
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS